JP6523461B2 - １７β−ＨＳＤ１−阻害剤のプロドラッグ - Google Patents
１７β−ＨＳＤ１−阻害剤のプロドラッグ Download PDFInfo
- Publication number
- JP6523461B2 JP6523461B2 JP2017533569A JP2017533569A JP6523461B2 JP 6523461 B2 JP6523461 B2 JP 6523461B2 JP 2017533569 A JP2017533569 A JP 2017533569A JP 2017533569 A JP2017533569 A JP 2017533569A JP 6523461 B2 JP6523461 B2 JP 6523461B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- decahydro
- cyclopenta
- methylthiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AHOJHUQRRYNNQK-IPEDDGMGSA-N CC(CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CC3)C1=C(CC(Cl)=C1O)C3=C1Cl)/C2=N/OC Chemical compound CC(CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CC3)C1=C(CC(Cl)=C1O)C3=C1Cl)/C2=N/OC AHOJHUQRRYNNQK-IPEDDGMGSA-N 0.000 description 1
- LTOBWULSPQOODY-UKRYKFHKSA-N CC(CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4)C1c3cc(Br)c4O)C2=O Chemical compound CC(CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4)C1c3cc(Br)c4O)C2=O LTOBWULSPQOODY-UKRYKFHKSA-N 0.000 description 1
- MJISNQSHIYISHR-VZRRMLPQSA-N C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4)C1c3cc(N)c4O)C2=O Chemical compound C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4)C1c3cc(N)c4O)C2=O MJISNQSHIYISHR-VZRRMLPQSA-N 0.000 description 1
- SHENHPUEPSSUEQ-JDBGQIMMSA-N C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4)C1c3ccc4O)/C2=N/O Chemical compound C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4)C1c3ccc4O)/C2=N/O SHENHPUEPSSUEQ-JDBGQIMMSA-N 0.000 description 1
- QYFBVEIPJPOCKA-WJTCXCBESA-N C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4)C1c3ccc4OC(C1NCCC1)=O)/C2=N/OC Chemical compound C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4)C1c3ccc4OC(C1NCCC1)=O)/C2=N/OC QYFBVEIPJPOCKA-WJTCXCBESA-N 0.000 description 1
- KIPQOYJRWWGQTK-IGGGATHQSA-N C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4Br)C1c3ccc4OP(O)(O)=O)C2=O Chemical compound C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4Br)C1c3ccc4OP(O)(O)=O)C2=O KIPQOYJRWWGQTK-IGGGATHQSA-N 0.000 description 1
- MSWKAXLKIVADDA-MHNWBSPISA-N C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4Cl)C1c3cc([N+]([O-])=O)c4O)C2=O Chemical compound C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4Cl)C1c3cc([N+]([O-])=O)c4O)C2=O MSWKAXLKIVADDA-MHNWBSPISA-N 0.000 description 1
- JSSHTKVXODCHTG-MHNWBSPISA-N C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4F)C1c3cc([N+]([O-])=O)c4O)C2=O Chemical compound C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4F)C1c3cc([N+]([O-])=O)c4O)C2=O JSSHTKVXODCHTG-MHNWBSPISA-N 0.000 description 1
- XWDQEWFLKZSAOO-MHNWBSPISA-N C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4[N+]([O-])=O)C1c3cc([N+]([O-])=O)c4O)C2=O Chemical compound C[C@](CC1)(C([C@H](CCC(Nc2ncc(C)[s]2)=O)C2)C(CCc3c4[N+]([O-])=O)C1c3cc([N+]([O-])=O)c4O)C2=O XWDQEWFLKZSAOO-MHNWBSPISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20146150 | 2014-12-23 | ||
| FI20146150 | 2014-12-23 | ||
| PCT/FI2015/050930 WO2016102776A1 (en) | 2014-12-23 | 2015-12-22 | Prodrugs of 17.beta.-hsd1 -inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501266A JP2018501266A (ja) | 2018-01-18 |
| JP2018501266A5 JP2018501266A5 (enExample) | 2019-01-17 |
| JP6523461B2 true JP6523461B2 (ja) | 2019-06-05 |
Family
ID=55221442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533569A Active JP6523461B2 (ja) | 2014-12-23 | 2015-12-22 | １７β−ＨＳＤ１−阻害剤のプロドラッグ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10413557B2 (enExample) |
| EP (1) | EP3237431B1 (enExample) |
| JP (1) | JP6523461B2 (enExample) |
| CN (1) | CN107207561B (enExample) |
| WO (1) | WO2016102776A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10626140B2 (en) * | 2014-12-23 | 2020-04-21 | Forendo Pharma Ltd | Prodrugs of 17β-HSD1-inhibitors |
| CN115716860A (zh) | 2017-06-08 | 2023-02-28 | 佛恩多制药有限公司 | 15β-[3-丙酰氨基]-取代的雌-1,3,5(10)-三烯-17-酮及17-肟 |
| WO2023122075A1 (en) * | 2021-12-20 | 2023-06-29 | Ohio State Innovation Foundation | Compositions comprising sterol-amino-phosphate compounds and methods of making and use thereof |
| WO2025185710A1 (zh) * | 2024-03-08 | 2025-09-12 | 长春金赛药业有限责任公司 | 17β-HSD1抑制剂化合物、药物组合物及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9908592A (pt) | 1998-03-11 | 2001-04-24 | Endorech Inc | Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit |
| EP1102753B1 (en) | 1998-08-07 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Pyrazoles as estrogen receptor modulators |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| KR100991616B1 (ko) | 2001-09-06 | 2010-11-04 | 쉐링 코포레이션 | 안드로겐 의존성 질환 치료용 17β-하이드록시스테로이드데하이드로게나제 유형 3 억제제 |
| PE20030705A1 (es) | 2001-10-17 | 2003-08-21 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes |
| US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| US7074795B2 (en) | 2002-11-18 | 2006-07-11 | Schering Corporation | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| CA2509758A1 (en) | 2002-12-17 | 2004-07-22 | Schering Corporation | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| US7015211B2 (en) | 2003-03-21 | 2006-03-21 | Yale University | 15α-substituted estradiol carboxylic acid esters as locally active estrogens |
| GB0306718D0 (en) | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| US8088758B2 (en) * | 2003-11-12 | 2012-01-03 | Abbott Products Gmbh | 17β-hydroxysteroid dehydrogenase type I inhibitors |
| TWI331154B (en) * | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| DE102004032673A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
| DE102004032674A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| ZA200709854B (en) * | 2005-05-26 | 2009-03-25 | Solvay Pharm Gmbh | 17ß-HSD1 and STS inhibitors |
| US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| MX2009002579A (es) | 2006-09-19 | 2009-03-20 | Solvay Pharm Gmbh | Derivados de estratrieno y sus usos como inhibidores de 17beta-hidroxiesteroide deshidrogenasa. |
| CN101568547B (zh) | 2006-11-30 | 2014-06-25 | 索尔瓦药物有限公司 | 作为17βHSD抑制剂的被取代的雌三烯衍生物 |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| TN2015000555A1 (en) | 2013-06-25 | 2017-04-06 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
| JP6461127B2 (ja) | 2013-06-25 | 2019-01-30 | フォレンド ファーマ リミテッド | １７βヒドロキシステロイド脱水素酵素、タイプＩの阻害剤としての治療活性エストラトリエンチアゾール誘導体 |
| US10626140B2 (en) | 2014-12-23 | 2020-04-21 | Forendo Pharma Ltd | Prodrugs of 17β-HSD1-inhibitors |
-
2015
- 2015-12-22 JP JP2017533569A patent/JP6523461B2/ja active Active
- 2015-12-22 EP EP15828340.8A patent/EP3237431B1/en active Active
- 2015-12-22 US US15/539,184 patent/US10413557B2/en active Active
- 2015-12-22 WO PCT/FI2015/050930 patent/WO2016102776A1/en not_active Ceased
- 2015-12-22 CN CN201580074140.6A patent/CN107207561B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170354664A1 (en) | 2017-12-14 |
| EP3237431B1 (en) | 2019-03-20 |
| WO2016102776A1 (en) | 2016-06-30 |
| US10413557B2 (en) | 2019-09-17 |
| JP2018501266A (ja) | 2018-01-18 |
| CN107207561A (zh) | 2017-09-26 |
| EP3237431A1 (en) | 2017-11-01 |
| CN107207561B (zh) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6556125B2 (ja) | １７β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての治療的に活性な１７−窒素置換エストラトリエンチアゾール誘導体 | |
| JP6523461B2 (ja) | １７β−ＨＳＤ１−阻害剤のプロドラッグ | |
| JP6461127B2 (ja) | １７βヒドロキシステロイド脱水素酵素、タイプＩの阻害剤としての治療活性エストラトリエンチアゾール誘導体 | |
| CN105518017B (zh) | 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物 | |
| JP6545266B2 (ja) | １７β‐ＨＳＤ１抑制剤のプロドラッグ | |
| JP7417608B2 (ja) | １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物 | |
| HK1205743B (en) | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments | |
| HK1205743A1 (en) | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170816 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180530 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180814 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181128 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20181128 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190417 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190425 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6523461 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |